Altor BioScience
18
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
38.9%
7 terminated/withdrawn out of 18 trials
61.1%
-25.4% vs industry average
0%
0 trials in Phase 3/4
100%
11 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
CIML NK Cell in Head & Neck Cancer
Role: collaborator
ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
Role: collaborator
QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803
Role: lead
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
Role: lead
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
Role: lead
PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14)
Role: lead
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
Role: lead
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Role: lead
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Role: lead
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Role: lead
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Role: lead
2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
Role: collaborator
QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel
Role: lead
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Role: lead
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
Role: lead
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Role: lead
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
Role: lead
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Role: lead
All 18 trials loaded